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Report of a Case
A 53-year-old woman presented to her local accident and emergency department in October 2011 with nausea and vomiting. She was noted to have an elevated unexplained, asymptomatic creatinine kinase level greater than 100 000 units/mL (normal range, 0-100 units/mL), was managed with supportive treatment, and recovered fully over the next 2 weeks. There were no features of polymyositis.
A few weeks later (November 2011), she developed bilateral lower-limb weakness, paresthesia, an incomplete sensation of bladder fullness, and constipation. On examination, she had bilateral hip flexor weakness (4/5) with reduced vibration sensation up to her left knee. Her creatinine kinase level had normalized. A magnetic resonance imaging scan showed transverse myelitis extending from T4 to T11. She was treated with intravenous methylprednisolone sodium succinate followed by a tapering course of oral prednisolone sodium phosphate and made a good recovery.
In February 2012, she developed a vesicobullous rash over both her elbows and arms that was pruritic and led to excoriation ( Figure 1) . This was treated with emollients and topical steroids with minimal improvement. A month later, she developed further paresthesias of both lower limbs, with a bandlike sensation around the abdomen, neuropathic pain, and worsening weakness of legs.
Her medical history was unremarkable except for irondeficiency anemia and bowel biopsy-proven celiac disease treated with a gluten-free diet.
Findings from her brain magnetic resonance imaging were normal and magnetic resonance imaging of the spine showed longitudinally extensive transverse myelitis involving both the cervical ( Figure 2 ) and thoracic spine. Blood test results for celiac disease serological markers (tissue transglutaminase and antigliadin antibodies) and autoantibody screen were nega-IMPORTANCE Neuromyelitis optica is associated with severe neurodisability if not recognized and treated promptly. Several autoimmune disorders are associated with this condition and may vary in their presentation. It is essential that clinicians are aware of the uncommon presenting features of neuromyelitis optica and associated autoimmune conditions. OBSERVATIONS A 53-year-old woman presented with nausea and vomiting and was noted to have an asymptomatic elevated creatinine kinase level, which improved with conservative management. She had a history of iron-deficiency anemia due to long-standing celiac disease that was managed with a gluten-free diet. She then presented with recurrent transverse myelitis and a vesicobullous rash over her arms and feet that was pruritic and excoriating. Skin biopsy results confirmed a clinical diagnosis of dermatitis herpetiformis and antibody test findings against aquaporin-4 were positive, leading to a diagnosis of neuromyelitis optica spectrum disorder. She was treated with methylprednisolone sodium succinate, plasma exchange, and azathioprine and has remained in remission.
CONCLUSIONS AND RELEVANCE This report highlights the association of neuromyelitis optica with dermatitis herpetiformis, which can present even without clinical features of celiac disease. Nausea, vomiting, and asymptomatic hyperCKemia should be recognized as rare presenting features of neuromyelitis optica.
tive. Results for anti-aquaporin-4 antibody (anti-AQP4 Ab) were positive and she was diagnosed as having NMO spectrum disorder (NMOSD).
Skin biopsy of the rash ( Figure 3 ) showed neutrophilic infiltrates, intercellular edema, and bullae formation with ulceration in the epidermis. Immunofluorescence showed granular deposition of IgA and complement 3 at the dermoepidermal junction. These appearances were consistent with dermatitis herpetiformis (DH).
The patient was treated initially with methylprednisolone followed by 5 cycles of plasma exchange, with some improvement. She was treated with azathioprine along with prednisolone and has remained relapse free for the last 18 months. Her rash of DH has not worsened after instituting a strict glutenfree diet.
Written informed consent was obtained from the patient, and institutional review board approval was obtained as part of the UK Neuromyelitis Optica Study from the Walton Centre.
Discussion
Although relapsing longitudinally extensive transverse myelitis immediately raises the possibility of NMO, this case presented many additional diagnostic difficulties: the skin rash, elevated creatinine kinase level, nausea, and vomiting. Neuromyelitis optica is a relapsing autoimmune disorder characterized by longitudinally extensive transverse myelitis and optic neuritis and is associated with significant disability if untreated. 1 A specific biomarker, an autoantibody against AQP4(anti-AQP4 Ab), is extremely sensitive and specific for its diagnosis. The prevalence of autoimmune conditions, both organ and nonorgan specific, with NMO is approximately 30%. The arrowhead points to an area of increased signal intensity involving more than 3 cervical segments, which is suggestive of longitudinally extensive transverse myelitis. The differential diagnosis for transverse myelitis associated with rash includes systemic lupus erythematosus, Behçet disease (rash is often a pathergy reaction), and antiphospholipid syndrome (livedo reticularis). It is increasingly recognized that systemic lupus erythematosus by itself rarely causes myelitis, and most patients with lupus myelitis have coexisting NMOSD. Many viral infections (herpes viruses 1 and 2, enterovirus, Epstein-Barr virus, cytomegalovirus, adenovirus, dengue, hepatitis A, varicella zoster, influenza, mumps, rubella, rubeola, human immunodeficiency virus, and human T-cell lymphotrophic virus 1) can cause myelopathy and rash. These were considered unlikely in our case. The biopsyproven celiac disease in the gut and the characteristic rash narrowed the dermatological diagnosis to DH, which was confirmed on biopsy.
Dermatitis herpetiformis is considered an extraintestinal manifestation of celiac disease, an immune enteropathy triggered by wheat gliadin. Although there are several reports on the association of celiac disease with NMO (Table) , [3] [4] [5] [6] [7] very few mention the association of DH with NMO. 6 The rash of DH is a chronic, pruritic, predominantly vesicobullous skin eruption. 8 The pathophysiology involves IgA autoantibodies against transglutaminase 3, which are deposited and cause inflammation on the papillary dermis. The rash has been described as polymorphic: papular, vesicular, or bullous and extremely pruritic, leading to excoriations and crusted erosions. These often lead to hypo/hyperpigmentation and lichenification in chronic cases. The characteristic distribution is on the elbows, knees, gluteal region, neck, and shoulders. Dermatitis herpetiformis can present at any age and usually gets better in sunny weather owing to the beneficial effects of sunshine.
Patients usually have a fluctuating course and spontaneous remission is rare. A skin biopsy shows findings of neutrophilic microabscesses at the papillary dermis tips, subepidermal bullae, and a granular IgA deposit on the papillary dermis. Several autoimmune disorders, such as thyroiditis, systemic lupus erythematosus, Sjögren syndrome, diabetes mellitus, primary biliary cirrhosis, pernicious anemia, vitiligo, alopecia areata, and pernicious anemia, are reported along with DH. 9 Although the enteropathy (classic celiac disease) is quiescent in cases of DH, the small-intestinal changes of villous atrophy and crypt hyperplasia are usually present and may lead to malabsorption and iron deficiency. In addition, DH along with celiac disease share an increased risk for lymphoproliferative malignancies like non-Hodgkin lymphoma. 10 The clinical differential diagnosis of the polymorphic rash seen in DH is wide and includes atopic dermatitis, herpetic infections, nummular eczema, dermatitis artifacta, scabies, or another immune blistering condition such as bullous pemphigoid. It is unlikely to be a hypersensitivity reaction to the medications used in the treatment of myelitis. Another interesting feature in our reported case is the occurrence of hyperCKemia during the initial presentation. HyperCKemia has been reported in selected cases to precede the onset of NMO and also recur during the relapse.
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Aquaporin-4 has been expressed in the fast-twitch skeletal muscle fibers and its expression has also been noted to be altered in some dystrophic muscles. However, muscle diseases have not been reported in NMO and the exact correlation of hyperCKemia with NMO is not fully understood. One postulation is that muscle destruction due to anti-AQP4 Ab augments cellular and humoral autoimmunity to AQP4 and triggers disruption of the blood-brain barrier and influx of the antibodies causing inflammation of the central nervous system. 11 Nausea, vomiting, and hiccough are associated with NMO. These represent brainstem involvement (area postrema) and may precede an episode. 12 The presence of these in the absence of a gastrointestinal cause should alert the physician to a brainstem pathology including NMO. This report aimed to highlight 3 aspects of NMOSD. First, the coexistence of DH with NMOSD. Because DH occurs mostly without symptoms of enteropathy, it is important to suspect a vesicobullous pruritic rash as DH and confirm the diagnosis with a dermatology consult, skin biopsy, and, if appropriate, small-bowel biopsy. Second, nausea and vomiting can be a presentation of NMOSD. Third, hyperCKemia can occur in NMO and is possibly related to skeletal muscle involvement. The presence of anti-AQP4 Ab supports NMOSD, predicts future relapses, and alerts the clinician to consider early immunomodulatory treatment and prompt aggressive treatment of relapses. 
